DE3177213D1
(de)
|
1980-04-03 |
1990-10-18 |
Biogen Inc |
Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen fibroblast-interferon.
|
IT1185503B
(it)
*
|
1984-01-11 |
1987-11-12 |
Univ New York |
Cloni di odna di eritropietina umana
|
JPS62501010A
(ja)
|
1984-12-04 |
1987-04-23 |
ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド |
エリトロポエチンの生産方法
|
IL77081A
(en)
*
|
1984-12-04 |
1999-10-28 |
Genetics Inst |
AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
|
US4677195A
(en)
*
|
1985-01-11 |
1987-06-30 |
Genetics Institute, Inc. |
Method for the purification of erythropoietin and erythropoietin compositions
|
US4745099A
(en)
*
|
1985-02-06 |
1988-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for the treatment of the anemia of malignant tumors
|
US4732889A
(en)
*
|
1985-02-06 |
1988-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
|
GB2177914B
(en)
*
|
1985-06-04 |
1989-10-25 |
Chugai Pharmaceutical Co Ltd |
A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
|
IL79176A
(en)
*
|
1985-06-20 |
1992-06-21 |
Kirin Amgen Inc |
Process for the recovery of erythropoietin from a fluid
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
JPS63500636A
(ja)
*
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするdna
|
US6004548A
(en)
*
|
1985-08-23 |
1999-12-21 |
Amgen, Inc. |
Analogs of pluripotent granulocyte colony-stimulating factor
|
US4935350A
(en)
*
|
1985-11-18 |
1990-06-19 |
Amgen |
Materials and methods for controlling plasmid copy number and stability
|
JPS62171696A
(ja)
*
|
1986-01-23 |
1987-07-28 |
Sumitomo Chem Co Ltd |
ヒトエリスロポエチンの製造方法
|
EP0236059B1
(en)
*
|
1986-02-27 |
1994-04-27 |
Snow Brand Milk Products Co. Ltd. |
Preparation of erythropoietin-producing cells and production process of erythropoietin using same
|
DK173067B1
(da)
|
1986-06-27 |
1999-12-13 |
Univ Washington |
Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
|
GR871029B
(en)
|
1986-07-14 |
1987-11-02 |
Genetics Inst |
Novel osteoinductive factors
|
US4954437A
(en)
*
|
1986-09-15 |
1990-09-04 |
Integrated Genetics, Inc. |
Cell encoding recombinant human erythropoietin
|
US5013718A
(en)
*
|
1986-11-21 |
1991-05-07 |
Amgen, Inc. |
Method for treating iron overload using EPO
|
WO1988005466A2
(en)
*
|
1987-01-15 |
1988-07-28 |
Codon |
Tandem gene eukaryotic expression vectors
|
US4835260A
(en)
*
|
1987-03-20 |
1989-05-30 |
Genetics Institute, Inc. |
Erythropoietin composition
|
JP2791418B2
(ja)
|
1987-12-02 |
1998-08-27 |
株式会社ミドリ十字 |
異種蛋白質の製造方法、組換えdna、形質転換体
|
DE3923963A1
(de)
*
|
1989-07-20 |
1991-01-31 |
Behringwerke Ag |
Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
|
US6932968B1
(en)
|
1989-07-26 |
2005-08-23 |
Dade Behring Marburg Gmbh |
Erythropoietin (EPO) peptides and antibodies directed against these
|
DE3924746A1
(de)
*
|
1989-07-26 |
1991-01-31 |
Behringwerke Ag |
Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
|
US7217689B1
(en)
|
1989-10-13 |
2007-05-15 |
Amgen Inc. |
Glycosylation analogs of erythropoietin
|
KR100221066B1
(ko)
*
|
1989-10-13 |
1999-10-01 |
스튜어트 엘.왓트 |
에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
|
DE4115722A1
(de)
*
|
1991-05-14 |
1992-11-19 |
Boehringer Mannheim Gmbh |
Serumfreies medium zur kultivierung von saeugerzellen
|
US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
US5968502A
(en)
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
NZ245015A
(en)
|
1991-11-05 |
1995-12-21 |
Transkaryotic Therapies Inc |
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
|
US5728536A
(en)
*
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US5505944A
(en)
*
|
1992-09-09 |
1996-04-09 |
Nippon Kayaku Kabushiki Kaisha |
Physiologically active substance NK175203, process for production thereof and pharmaceutical use thereof
|
WO1994024160A2
(en)
*
|
1993-04-21 |
1994-10-27 |
Brigham And Women's Hospital |
Erythropoietin muteins with enhanced activity
|
ZA946122B
(en)
*
|
1993-08-17 |
1995-03-20 |
Amgen Inc |
Erythropoietin analogs
|
US8192955B1
(en)
*
|
1994-01-03 |
2012-06-05 |
Genentech, Inc. |
Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
|
US5888774A
(en)
*
|
1994-12-19 |
1999-03-30 |
Cangene Corporation |
Recombinant DNA molecules and expression vectors for erythropoietin
|
IL118201A
(en)
*
|
1995-05-11 |
2004-12-15 |
Roche Diagnostics Gmbh |
Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
|
WO1996040749A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Johnson & Johnson Corporation |
Compounds and peptides that bind to the erythropoietin receptor
|
ES2333425T5
(es)
|
1995-06-15 |
2012-08-28 |
Crucell Holland B.V. |
Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
|
JPH10510434A
(ja)
*
|
1995-07-07 |
1998-10-13 |
ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cmp−n−アセチルノイラミン酸ヒドロキシラーゼをコードする核酸及び修飾糖タンパク質の産生のためのその使用
|
EP0752474A1
(en)
*
|
1995-07-07 |
1997-01-08 |
Boehringer Mannheim Gmbh |
Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
|
PT888385E
(pt)
|
1996-03-14 |
2004-01-30 |
Genentech Inc |
Utilizacoes de gdnf e de receptores de gdnf
|
GB2318352A
(en)
*
|
1996-06-25 |
1998-04-22 |
Dejan Markovic |
Polypeptides mimicking the activity of human erythropoietin
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
WO1998047922A2
(en)
*
|
1997-04-21 |
1998-10-29 |
Glycozyme, Inc. |
Determination of recombinant glycosylated proteins and peptides in biological fluids
|
US6475725B1
(en)
*
|
1997-06-20 |
2002-11-05 |
Baxter Aktiengesellschaft |
Recombinant cell clones having increased stability and methods of making and using the same
|
DE19729769A1
(de)
|
1997-07-11 |
1999-01-14 |
Cardiogene Gentherapeutische S |
Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie
|
US6017876A
(en)
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US7316923B1
(en)
|
1997-09-26 |
2008-01-08 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
US6897066B1
(en)
|
1997-09-26 |
2005-05-24 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
WO1999019472A1
(en)
*
|
1997-10-16 |
1999-04-22 |
University Of Georgia Research Foundation, Inc. |
Vectors comprising a magnum-specific promoter for avian transgenesis
|
ATE267215T1
(de)
*
|
1997-12-08 |
2004-06-15 |
Lexigen Pharm Corp |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
JP2002504330A
(ja)
*
|
1998-02-19 |
2002-02-12 |
イースターン・バージニア・メディカル・スクール |
組換え型活性ヒト透明帯タンパク質3(hZP3)
|
US7037663B2
(en)
*
|
1998-02-19 |
2006-05-02 |
Eastern Virginia Medical School |
Human zona pellucida protein 3 and uses thereof
|
PT937456E
(pt)
|
1998-02-23 |
2004-10-29 |
Cilag Ag Int |
Dispersao lipossomal de eritropoietina
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
KR100434729B1
(ko)
*
|
1998-03-18 |
2004-11-03 |
주식회사 엘지생명과학 |
천연 추출물을 첨가하여 중국햄스터 난소 유래세포에서 에리스로포이에틴의 생산 증대방법
|
AU757549B2
(en)
*
|
1998-03-27 |
2003-02-27 |
Cytos Biotechnology Ag |
Inducible alphaviral gene expression system
|
AR019025A1
(es)
|
1998-04-09 |
2001-12-26 |
Roche Diagnostics Gmbh |
Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
|
JP2002511432A
(ja)
*
|
1998-04-15 |
2002-04-16 |
レキシジェン ファーマシューティカルズ コーポレイション |
新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
WO1999054486A1
(en)
|
1998-04-22 |
1999-10-28 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
DE69933216T2
(de)
|
1998-06-15 |
2007-09-20 |
GTC Biotherapeutics, Inc., Framingham |
Erythropoietin-analog-menschliches serum-albumin fusionsprotein
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
US6451579B1
(en)
|
1998-07-29 |
2002-09-17 |
Invitrogen Corporation |
Regulated expression of recombinant proteins using RNA viruses
|
EP0984062A1
(en)
*
|
1998-09-04 |
2000-03-08 |
Cytos Biotechnology AG |
Production of human erythropoietin
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7304150B1
(en)
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
BR9917606A
(pt)
|
1998-11-06 |
2002-12-31 |
Bio Sidus S A |
Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
|
BR9905867A
(pt)
|
1998-11-06 |
2001-01-23 |
Bio Sidus S A |
Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
|
BR9905868A
(pt)
|
1998-11-06 |
2001-01-23 |
Bio Sidus S A |
Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
|
DE19857609A1
(de)
|
1998-12-14 |
2000-06-15 |
Hannelore Ehrenreich |
Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
US6451346B1
(en)
*
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
DE19905501B4
(de)
|
1999-02-10 |
2005-05-19 |
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie |
Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
|
US7309687B1
(en)
|
1999-04-13 |
2007-12-18 |
The Kenneth S. Warren Institute, Inc. |
Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
US20050170463A1
(en)
*
|
1999-04-15 |
2005-08-04 |
Abraham Bout |
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
|
US8236561B2
(en)
*
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
US7297680B2
(en)
*
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
US6855544B1
(en)
*
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
US7604960B2
(en)
*
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
JP3660880B2
(ja)
*
|
1999-05-07 |
2005-06-15 |
ジェネンテック・インコーポレーテッド |
新規なチンパンジーエリスロポエチン(chepo)ポリペプチドおよびこれをコードする核酸
|
US6555343B1
(en)
|
1999-05-07 |
2003-04-29 |
Genentech Inc. |
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
|
US6831060B2
(en)
|
1999-05-07 |
2004-12-14 |
Genentech, Inc. |
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
|
AT409379B
(de)
|
1999-06-02 |
2002-07-25 |
Baxter Ag |
Medium zur protein- und serumfreien kultivierung von zellen
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US6737519B1
(en)
|
1999-07-30 |
2004-05-18 |
Genome Therapeutics Corporation |
Human genes relating to respiratory diseases and obesity
|
HUP0202442A3
(en)
*
|
1999-08-09 |
2005-01-28 |
Lexigen Pharmaceuticals Corp L |
Multiple cytokine-antibody complexes
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
EP1228214A2
(en)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietin forms with improved properties
|
US6703480B1
(en)
|
1999-11-24 |
2004-03-09 |
Palani Balu |
Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
|
US7527961B2
(en)
*
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
US7521220B2
(en)
*
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
WO2001042442A2
(en)
|
1999-12-10 |
2001-06-14 |
Cytos Biotechnology Ag |
Activation of endogenous genes by genomic introduction of a replicon
|
ATE336514T1
(de)
*
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2405701A1
(en)
*
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
IES20010462A2
(en)
*
|
2000-05-12 |
2001-11-14 |
Cyril John Higgins |
Use of the world wide web
|
PT1294401E
(pt)
*
|
2000-06-29 |
2007-11-09 |
Merck Patent Gmbh |
Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
|
WO2002006456A1
(en)
*
|
2000-07-13 |
2002-01-24 |
Invitrogen Corporation |
Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
|
US7855229B2
(en)
*
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7645898B2
(en)
*
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
WO2002024899A2
(en)
|
2000-09-25 |
2002-03-28 |
Valentis, Inc. |
Improved system for regulation of transgene expression
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
AU2002233230B2
(en)
|
2000-12-20 |
2007-02-01 |
F. Hoffmann-La Roche Ag |
Erythropoietin conjugates
|
US6531121B2
(en)
|
2000-12-29 |
2003-03-11 |
The Kenneth S. Warren Institute, Inc. |
Protection and enhancement of erythropoietin-responsive cells, tissues and organs
|
US7767643B2
(en)
*
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
KR100399337B1
(ko)
*
|
2001-02-07 |
2003-09-26 |
드림바이오젠 주식회사 |
단백질의 무세포 번역후수식법
|
KR20090010127A
(ko)
|
2001-03-07 |
2009-01-28 |
메르크 파텐트 게엠베하 |
하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
DK1383785T3
(da)
|
2001-05-03 |
2011-05-23 |
Merck Patent Gmbh |
Rekombinant tumorspecifikt antistof og anvendelse deraf
|
AU2002310122A1
(en)
*
|
2001-05-25 |
2002-12-09 |
Human Genome Sciences, Inc. |
Chemokine beta-1 fusion proteins
|
EP1421104A4
(en)
*
|
2001-08-02 |
2005-08-24 |
Trinity Biomedical Technology |
HUMANE ZONA PELLUCIDA PROTEINS AND METHOD FOR THEIR USE IN THE DIAGNOSIS OF MALE INFERENCE
|
JP3993560B2
(ja)
*
|
2001-08-30 |
2007-10-17 |
ステム セル セラピューティクス インコーポレイテッド |
神経幹細胞の分化およびその治療用途
|
US20030104996A1
(en)
*
|
2001-08-30 |
2003-06-05 |
Tiansheng Li |
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
EP1430114B1
(en)
|
2001-09-14 |
2012-01-18 |
Stem Cell Therapeutics Inc. |
Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
|
AR036402A1
(es)
*
|
2001-09-18 |
2004-09-08 |
Stem Cell Therapeutics Inc |
Efecto de la hormona de crecimiento y de igf-1 sobre celulas madre neuronales.
|
WO2003045995A2
(en)
*
|
2001-11-28 |
2003-06-05 |
Sandoz Gmbh |
Cell culture process
|
ATE542137T1
(de)
*
|
2001-12-04 |
2012-02-15 |
Merck Patent Gmbh |
Immunocytokine mit modulierter selektivität
|
US20070161608A1
(en)
*
|
2001-12-06 |
2007-07-12 |
Dalton James T |
Selective androgen receptor modulators for treating muscle wasting
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
KR100979025B1
(ko)
*
|
2001-12-07 |
2010-08-30 |
크루셀 홀란드 비.브이. |
바이러스, 바이러스 단리물 및 백신의 생산
|
CA2471363C
(en)
*
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR100982922B1
(ko)
|
2002-01-17 |
2010-09-20 |
론자 바이올로직스 피엘씨 |
단백질을 생산할 수 있으며 무글루타민 배지에서 성장할 수있는 글루타민-요구성 인간세포
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
CA2485365A1
(en)
*
|
2002-05-13 |
2003-11-20 |
Modigenetech Ltd. |
Ctp-extended erythropoietin
|
NZ537306A
(en)
*
|
2002-07-01 |
2008-11-28 |
Kenneth S Warren Inst Inc |
Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
|
CN101058800B
(zh)
|
2002-07-09 |
2013-03-13 |
巴克斯特国际有限公司 |
用于细胞培养的无动物蛋白质培养基
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
US7368115B2
(en)
*
|
2002-07-31 |
2008-05-06 |
Stem Cell Therapeutics Inc. |
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
|
CN1684978A
(zh)
*
|
2002-08-31 |
2005-10-19 |
希杰株式会社 |
糖基化的人粒细胞集落刺激因子(g-csf)同种型
|
US7611700B2
(en)
*
|
2002-09-09 |
2009-11-03 |
Hanall Pharmaceuticals, Co., Ltd. |
Protease resistant modified interferon alpha polypeptides
|
EP1681303B1
(en)
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
RU2328505C2
(ru)
|
2002-09-11 |
2008-07-10 |
Фрезениус Каби Дойчланд Гмбх |
Полипептиды, обработанные has, особенно эритропоэтин, обработанный has
|
DE20321793U1
(de)
|
2002-09-11 |
2010-06-02 |
Fresenius Kabi Deutschland Gmbh |
Hydroxyalkylstärke-Derivate
|
US7538092B2
(en)
|
2002-10-08 |
2009-05-26 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
WO2004055056A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Merck Patent Gmbh |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
EP1594530A4
(en)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
HYBRID PROTEINS OF ALBUMIN
|
ZA200506196B
(en)
*
|
2003-02-03 |
2006-10-25 |
Japan Immuno Inc |
High-expression vector for animal cells
|
EP1624883A4
(en)
*
|
2003-04-09 |
2008-11-26 |
Univ Utah Res Found |
COMPOSITIONS AND METHODS RELATING TO THE PRODUCTION OF ERYTHROPOIETIN
|
US7459152B2
(en)
*
|
2003-04-23 |
2008-12-02 |
Rush University Medical Center |
Erythropoietin administration to improve graft survival
|
EP1623023B1
(en)
*
|
2003-05-09 |
2008-11-12 |
Crucell Holland B.V. |
Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
|
DE602004028725D1
(de)
*
|
2003-05-12 |
2010-09-30 |
Affymax Inc |
Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
|
KR20120094001A
(ko)
*
|
2003-05-12 |
2012-08-23 |
아피맥스, 인크. |
에리스로포이에틴 수용체에 결합하는 펩티드
|
WO2004100997A2
(en)
|
2003-05-12 |
2004-11-25 |
Affymax, Inc. |
Spacer moiety for poly(ethylene glycol) -modified peptides
|
AU2004238870B8
(en)
*
|
2003-05-12 |
2010-04-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
WO2004104046A1
(en)
*
|
2003-05-23 |
2004-12-02 |
Crucell Holland B.V. |
Production of recombinant igm in per.c6 cells
|
EP1641486B1
(en)
|
2003-06-10 |
2012-04-18 |
LG Life Sciences Ltd. |
Stable, aqueous solution of human erythropoietin, not containing serum albumin
|
EP1660631B1
(en)
*
|
2003-08-01 |
2013-04-24 |
Life Technologies Corporation |
Compositions and methods for purifying short rna molecules
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
BRPI0414887A
(pt)
|
2003-09-29 |
2006-12-12 |
Warren Pharmaceuticals Inc E T |
métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
|
PL2233150T3
(pl)
|
2003-12-30 |
2017-06-30 |
Bader |
Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek
|
WO2005067889A1
(en)
|
2003-12-30 |
2005-07-28 |
Durect Corporation |
Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
|
RU2370276C2
(ru)
*
|
2003-12-31 |
2009-10-20 |
Мерк Патент Гмбх |
Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
|
DE102004063927A1
(de)
|
2004-01-23 |
2005-12-15 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
ATE556716T1
(de)
|
2004-02-13 |
2012-05-15 |
Stem Cell Therapeutics Corp |
Verwendung des luteinisierenden hormons (lh) und von choriongonadotrophin (hcg) für die proliferation von neuralen stammzellen und neurogenese
|
US7255288B2
(en)
*
|
2004-03-08 |
2007-08-14 |
Wan Shan Chan |
Aroma therapy for fountain
|
EP1732609B1
(en)
|
2004-03-11 |
2012-07-11 |
Fresenius Kabi Deutschland GmbH |
Conjugates of hydroxyalkyl starch and a protein
|
TWI417303B
(zh)
|
2004-03-11 |
2013-12-01 |
Fresenius Kabi De Gmbh |
經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物
|
US7588745B2
(en)
*
|
2004-04-13 |
2009-09-15 |
Si Options, Llc |
Silicon-containing products
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US20110237664A1
(en)
*
|
2004-06-07 |
2011-09-29 |
Dalton James T |
Selective androgen receptor modulators for treating diabetes
|
US20060094104A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Leopold Grillberger |
Animal protein-free media for cultivation of cells
|
WO2006060148A2
(en)
*
|
2004-11-11 |
2006-06-08 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
WO2006061853A2
(en)
*
|
2004-12-10 |
2006-06-15 |
Serum Institute Of India Limited |
Novel erythropoietic compounds and a process for producing erythropoietic compounds
|
WO2006089228A2
(en)
*
|
2005-02-16 |
2006-08-24 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
EP2425715B1
(en)
|
2005-08-31 |
2014-03-05 |
University of Tennessee Research Foundation |
Treating symptoms of renal disease with selective androgen receptor modulators (SARM)
|
EP1762250A1
(en)
|
2005-09-12 |
2007-03-14 |
Fresenius Kabi Deutschland GmbH |
Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
|
US7534765B2
(en)
*
|
2005-09-27 |
2009-05-19 |
Stem Cell Therapeutics Corp. |
Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
|
WO2008048671A1
(en)
*
|
2006-10-18 |
2008-04-24 |
University Of Illinois |
Embryonic-like stem cells derived from adult human peripheral blood and methods of use
|
US9388382B2
(en)
*
|
2005-10-05 |
2016-07-12 |
The Board Of Trustees Of The University Of Illinois |
Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
|
EP1966237A2
(en)
*
|
2005-11-24 |
2008-09-10 |
Laboratoires Serono SA |
Erythropoietin polypeptides and uses thereof
|
SI1957630T2
(sl)
*
|
2005-12-08 |
2023-07-31 |
Amgen Inc. |
Izboljšana proizvodnja glikoproteinov z uporabo mangana
|
DK2522717T3
(da)
|
2006-01-04 |
2014-04-22 |
Baxter Int |
Oligopeptid-frie cellekulturmedier
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
DE102006004008A1
(de)
|
2006-01-27 |
2007-08-02 |
Hannelore Prof. Dr. Dr. Ehrenreich |
Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
|
EP2004212A4
(en)
*
|
2006-03-17 |
2010-07-14 |
Stem Cell Therapeutics Corp |
CONTINUOUS DOSING SCHEMES FOR NEURAL STEM CELL PROLIFERATING AGENTS AND NEURAL STEM CELL DIFFERENTIATING AGENTS
|
US8546329B2
(en)
|
2006-03-22 |
2013-10-01 |
Chugai Seiyaku Kabushiki Kaisha |
Erythropoietin solution preparation
|
CN101062407A
(zh)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
促红细胞生成素在预防或治疗视网膜损伤中的用途
|
EA018258B1
(ru)
|
2006-07-12 |
2013-06-28 |
Юниверсити Оф Теннесси Рисерч Фаундейшн |
Замещенный ациланилид и содержащие его композиции и способы лечения
|
KR20090046923A
(ko)
|
2006-08-04 |
2009-05-11 |
프로롱 파마슈티컬스, 인크. |
수식된 에리스로포이에틴
|
JPWO2008023725A1
(ja)
|
2006-08-22 |
2010-01-14 |
中外製薬株式会社 |
末梢神経障害の予防および/または治療剤
|
PL2054049T3
(pl)
|
2006-08-24 |
2016-11-30 |
|
Podstawione acyloanilidy i sposoby ich stosowania
|
JP2010504909A
(ja)
*
|
2006-09-14 |
2010-02-18 |
メドジェニクス・メディカル・イスラエル・リミテッド |
長期持続性の医薬製剤
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
WO2008065372A2
(en)
|
2006-11-28 |
2008-06-05 |
Nautilus Biotech, S.A. |
Modified erythropoietin polypeptides and uses thereof for treatment
|
JP5065391B2
(ja)
*
|
2006-12-06 |
2012-10-31 |
日本ケミカルリサーチ株式会社 |
ヒトエリスロポエチンの製造方法
|
EP2121017A2
(en)
*
|
2006-12-19 |
2009-11-25 |
Nokad |
Method for inhibiting the expression of endogenous erythropoietin (epo)
|
EP2111412A2
(en)
*
|
2007-02-02 |
2009-10-28 |
Amgen, Inc |
Hepcidin and hepcidin antibodies
|
AR065613A1
(es)
|
2007-03-09 |
2009-06-17 |
Chugai Pharmaceutical Co Ltd |
Agentes de proteccion para organos transplantados
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
US20100172919A1
(en)
|
2007-06-15 |
2010-07-08 |
Jan Grimm |
Noveltreatment for neurological disorders
|
WO2009010107A1
(en)
|
2007-07-19 |
2009-01-22 |
Hannelore Ehrenreich |
Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
|
WO2009012600A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Novagen Holding Corporation |
Fusion proteins
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
EP2205280B1
(en)
|
2007-09-27 |
2019-09-04 |
Amgen Inc. |
Pharmaceutical formulations
|
US8796206B2
(en)
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
EP2070950A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkyl starch derivatives and process for their preparation
|
MX2010008096A
(es)
|
2008-01-25 |
2010-09-22 |
Amgen Inc |
Anticuerpos de ferroportina y metodos de uso.
|
NZ602170A
(en)
|
2008-02-08 |
2014-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
ES2616021T3
(es)
|
2008-02-27 |
2017-06-09 |
National University Corporation Hokkaido University |
Vector de expresión para producción masiva de proteína derivada de un gen foráneo usando células animales y su uso
|
EP2095829A1
(en)
|
2008-02-27 |
2009-09-02 |
LEK Pharmaceuticals D.D. |
Selenium containing modifying agents and conjugates
|
MX2010011717A
(es)
|
2008-05-01 |
2010-11-30 |
Amgen Inc |
Anticuerpos anti-hepcidina y metodos de uso.
|
DE102008002209A1
(de)
|
2008-06-04 |
2009-12-10 |
Evonik Degussa Gmbh |
Verfahren zur Aufreinigung von Erythropoietin
|
DE102008002210A1
(de)
*
|
2008-06-04 |
2009-12-10 |
Evonik Degussa Gmbh |
Verfahren zur fermentativen Herstellung von Erythropoietin
|
WO2009155481A1
(en)
*
|
2008-06-20 |
2009-12-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
US20120172299A1
(en)
|
2008-09-23 |
2012-07-05 |
F. Hoffmann-La Roche Ag |
Purification of erythropoietin
|
MX2011003272A
(es)
*
|
2008-09-26 |
2011-04-28 |
Ambrx Inc |
Polipeptidos de eritropoyetina animal modificados y sus usos.
|
CN102215869B
(zh)
|
2008-11-13 |
2015-05-13 |
通用医疗公司 |
用于通过调整bmp-6来调节铁稳态的方法和组合物
|
DE102008054716A1
(de)
|
2008-12-16 |
2010-06-17 |
Evonik Degussa Gmbh |
Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
|
US9096878B2
(en)
|
2008-12-22 |
2015-08-04 |
National University Corporation Hokkaido University |
Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof
|
US20100272816A1
(en)
|
2009-04-27 |
2010-10-28 |
Wolfgang Rudinger |
Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
|
SG10202109219SA
(en)
|
2009-05-02 |
2021-10-28 |
Genzyme Corp |
Gene therapy for neurodegenerative disorders
|
UA107678C2
(uk)
|
2009-09-23 |
2015-02-10 |
ратіофарм ГмбХ |
Процес очищення рекомбінантного людського еритропоетину (епо), епо, очищений таким чином, та фармацевтична композиція, що містить його
|
EP2490957B1
(en)
|
2009-10-23 |
2016-11-23 |
Amgen, Inc |
Vial adapter and system
|
BR112012031121B1
(pt)
|
2010-06-07 |
2022-09-27 |
Amgen Inc |
Dispositivo de distribuição de drogas, kit e método de operar um dispositivo de distribuição de droga utilizável
|
EP2582396A4
(en)
|
2010-06-15 |
2014-01-01 |
Medgenics Medical Israel Ltd |
REMEDY FORMULATIONS WITH LONG-TERM EFFECT
|
MX349054B
(es)
|
2010-09-28 |
2017-07-07 |
Aegerion Pharmaceuticals Inc |
Leptinas altamente solubles.
|
MX341790B
(es)
|
2011-03-31 |
2016-09-02 |
Amgen Inc |
Adaptador de viales y sistema.
|
SI2699293T1
(sl)
|
2011-04-20 |
2019-05-31 |
Amgen Inc. |
Avtoinjekcijski aparat
|
KR102222187B1
(ko)
|
2011-10-14 |
2021-03-03 |
암젠 인크 |
주사기 및 어셈블리 방법
|
KR101443257B1
(ko)
*
|
2011-10-18 |
2014-09-19 |
주식회사 종근당 |
낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
|
EP2771301B1
(en)
|
2011-10-25 |
2017-12-20 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
KR102122941B1
(ko)
|
2012-07-13 |
2020-06-15 |
지티엑스, 인코포레이티드 |
선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9650411B2
(en)
|
2012-08-07 |
2017-05-16 |
Kyowa Hakko Kirin Co., Ltd. |
Method of purifying protein
|
ES2633960T3
(es)
|
2012-10-15 |
2017-09-26 |
Bristol-Myers Squibb Company |
Procesos de cultivo de células de mamífero para la producción de proteínas
|
US20150290390A1
(en)
|
2012-11-21 |
2015-10-15 |
Amgen Inc. |
Drug delivery device
|
ES2797974T3
(es)
|
2013-03-14 |
2020-12-04 |
Translate Bio Inc |
Acidos ribonucleicos con nucleótidos modificados con 4-tio y procedimientos relacionados
|
EP2968760B1
(en)
|
2013-03-15 |
2024-01-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
BR112015022123B1
(pt)
|
2013-03-15 |
2022-08-09 |
Intrinsic Lifesciences, Llc |
Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
|
US10066001B2
(en)
|
2013-03-15 |
2018-09-04 |
Apotex Inc. |
Enhanced liquid formulation stability of erythropoietin alpha through purification processing
|
TWI639453B
(zh)
|
2013-03-15 |
2018-11-01 |
美商安美基公司 |
用於注射器之匣盒
|
EP3831427A1
(en)
|
2013-03-22 |
2021-06-09 |
Amgen Inc. |
Injector and method of assembly
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
WO2015024977A1
(en)
|
2013-08-20 |
2015-02-26 |
Lek Pharmaceuticals D.D. |
CELL CULTURE MEDIUM AND PROCESS FOR CONTROLLING α-AMIDATION AND/OR C-TERMINAL AMINO ACID CLEAVAGE OF POLYPEPTIDES
|
AU2014340174B2
(en)
|
2013-10-24 |
2019-09-12 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
PL3060275T3
(pl)
|
2013-10-24 |
2019-12-31 |
Amgen Inc. |
Wstrzykiwacz i sposób montażu
|
US20150118187A1
(en)
|
2013-10-24 |
2015-04-30 |
Medgenics Medical Israel Ltd. |
Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
|
WO2015119906A1
(en)
|
2014-02-05 |
2015-08-13 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
EP3139977B1
(en)
|
2014-05-07 |
2021-02-17 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
WO2015181676A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
IL281354B2
(en)
|
2014-06-03 |
2024-06-01 |
Amgen Inc |
Devices and methods to assist the user of a drug delivery device
|
CA2961917A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
JP6766040B2
(ja)
|
2014-10-14 |
2020-10-07 |
アムジエン・インコーポレーテツド |
視覚および可聴インジケータを備える薬剤注射装置
|
WO2016100781A1
(en)
|
2014-12-19 |
2016-06-23 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
EP3233159B1
(en)
|
2014-12-19 |
2020-03-04 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
AU2016220141B2
(en)
|
2015-02-17 |
2018-07-12 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
EP3261690B1
(en)
|
2015-02-27 |
2021-12-15 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
WO2017068051A1
(en)
|
2015-10-21 |
2017-04-27 |
Lek Pharmaceuticals D.D. |
Peg-based dendron and process for producing the same
|
JP7082568B2
(ja)
|
2015-12-09 |
2022-06-08 |
アムジエン・インコーポレーテツド |
信号伝達キャップ付き自動注射器
|
WO2017120178A1
(en)
|
2016-01-06 |
2017-07-13 |
Amgen Inc. |
Auto-injector with signaling electronics
|
ES2814287T3
(es)
|
2016-03-15 |
2021-03-26 |
Amgen Inc |
Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
|
US11541168B2
(en)
|
2016-04-29 |
2023-01-03 |
Amgen Inc. |
Drug delivery device with messaging label
|
WO2017192287A1
(en)
|
2016-05-02 |
2017-11-09 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
JP7309363B2
(ja)
|
2016-05-13 |
2023-07-18 |
アムジエン・インコーポレーテツド |
バイアル・スリーブ組立体
|
US11238150B2
(en)
|
2016-05-16 |
2022-02-01 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
US11541176B2
(en)
|
2016-06-03 |
2023-01-03 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
EP3478342A1
(en)
|
2016-07-01 |
2019-05-08 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
US20190328965A1
(en)
|
2016-08-17 |
2019-10-31 |
Amgen Inc. |
Drug delivery device with placement detection
|
WO2018081234A1
(en)
|
2016-10-25 |
2018-05-03 |
Amgen Inc. |
On-body injector
|
AU2018210301A1
(en)
|
2017-01-17 |
2019-08-01 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
AU2018221351B2
(en)
|
2017-02-17 |
2023-02-23 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
CA3048520A1
(en)
|
2017-02-17 |
2018-08-23 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
CA3050927A1
(en)
|
2017-03-06 |
2018-09-13 |
Brian Stonecipher |
Drug delivery device with activation prevention feature
|
KR102627069B1
(ko)
|
2017-03-07 |
2024-01-18 |
암겐 인코포레이티드 |
과압에 의한 바늘 삽입
|
KR20240005194A
(ko)
|
2017-03-09 |
2024-01-11 |
암겐 인코포레이티드 |
약물 전달 장치용 삽입 메커니즘
|
EP3570871B1
(en)
|
2017-03-20 |
2020-11-18 |
H. Hoffnabb-La Roche Ag |
Method for in vitro glycoengineering of an erythropoiesis stimulating protein
|
ES2959935T3
(es)
|
2017-03-28 |
2024-02-29 |
Amgen Inc |
Sistema y método de vástago de émbolo y conjunto de jeringa
|
CN110709121B
(zh)
|
2017-06-08 |
2022-06-24 |
安进公司 |
扭矩驱动式药物递送装置
|
US11590294B2
(en)
|
2017-06-08 |
2023-02-28 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
KR102268647B1
(ko)
|
2017-06-12 |
2021-06-23 |
한국코러스 주식회사 |
안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법
|
US11541183B2
(en)
|
2017-06-22 |
2023-01-03 |
Amgen Inc. |
Device activation impact/shock reduction
|
US11395880B2
(en)
|
2017-06-23 |
2022-07-26 |
Amgen Inc. |
Electronic drug delivery device
|
MA49562A
(fr)
|
2017-07-14 |
2020-05-20 |
Amgen Inc |
Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
|
IL271173B2
(en)
|
2017-07-21 |
2024-04-01 |
Amgen Inc |
Gas permeable sealing element for drug container and methods of assembly
|
WO2019022950A1
(en)
|
2017-07-25 |
2019-01-31 |
Amgen Inc. |
DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
|
EP3658203B1
(en)
|
2017-07-25 |
2022-08-31 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
WO2019032482A2
(en)
|
2017-08-09 |
2019-02-14 |
Amgen Inc. |
HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
|
US11077246B2
(en)
|
2017-08-18 |
2021-08-03 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
WO2019070472A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
|
WO2019070552A1
(en)
|
2017-10-06 |
2019-04-11 |
Amgen Inc. |
DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
|
IL273323B1
(en)
|
2017-10-09 |
2024-06-01 |
Amgen Inc |
Drug delivery device with drive assembly and related assembly method
|
EP3703779A1
(en)
|
2017-11-03 |
2020-09-09 |
Amgen Inc. |
Systems and approaches for sterilizing a drug delivery device
|
US20200338271A1
(en)
|
2017-11-06 |
2020-10-29 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
JP2021501616A
(ja)
|
2017-11-06 |
2021-01-21 |
アムジエン・インコーポレーテツド |
配置及び流量検出を備える薬物送達デバイス
|
EP3706826A1
(en)
|
2017-11-10 |
2020-09-16 |
Amgen Inc. |
Plungers for drug delivery devices
|
AU2018368338A1
(en)
|
2017-11-16 |
2020-04-09 |
Amgen Inc. |
Autoinjector with stall and end point detection
|
CA3079540A1
(en)
|
2017-11-16 |
2019-05-23 |
Amgen Inc. |
Door latch mechanism for drug delivery device
|
KR20210013036A
(ko)
|
2018-05-24 |
2021-02-03 |
국립대학법인 홋가이도 다이가쿠 |
신규 벡터 및 그 이용
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
WO2020023444A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
MX2021000749A
(es)
|
2018-07-24 |
2021-03-29 |
Amgen Inc |
Dispositivos de suministro para administrar farmacos.
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
US20210260279A1
(en)
|
2018-07-24 |
2021-08-26 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
WO2020028009A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
AU2019347710A1
(en)
|
2018-09-24 |
2021-02-04 |
Amgen Inc. |
Interventional dosing systems and methods
|
WO2020068476A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
MX2021003492A
(es)
|
2018-10-02 |
2021-06-18 |
Amgen Inc |
Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
|
MX2021003491A
(es)
|
2018-10-05 |
2021-06-18 |
Amgen Inc |
Dispositivo de administracion de farmacos con indicador de dosis.
|
EA202191038A1
(ru)
|
2018-10-15 |
2021-07-06 |
Эмджен Инк. |
Способ платформенной сборки для устройства доставки лекарственного средства
|
MA53912A
(fr)
|
2018-10-15 |
2022-01-19 |
Amgen Inc |
Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
|
AU2019370159A1
(en)
|
2018-11-01 |
2021-04-22 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
EP3873566A1
(en)
|
2018-11-01 |
2021-09-08 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
AU2020263289A1
(en)
|
2019-04-24 |
2021-09-16 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
AU2020337250A1
(en)
|
2019-08-23 |
2022-03-03 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
MX2023013640A
(es)
|
2021-05-21 |
2023-11-30 |
Amgen Inc |
Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023209074A1
(en)
|
2022-04-28 |
2023-11-02 |
Institut National de la Santé et de la Recherche Médicale |
Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
|
WO2024094457A1
(en)
|
2022-11-02 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Method for producing glycoprotein compositions
|